S
Su-Xia Li
Researcher at Chinese PLA General Hospital
Publications - 11
Citations - 566
Su-Xia Li is an academic researcher from Chinese PLA General Hospital. The author has contributed to research in topics: Chemotherapy & Cancer. The author has an hindex of 6, co-authored 11 publications receiving 443 citations.
Papers
More filters
Journal ArticleDOI
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.
Chunmeng Wang,Zhiqiang Wu,Yao Wang,Yelei Guo,Hanren Dai,Xiaohui Wang,Xiang Li,Yajing Zhang,Wenying Zhang,Meixia Chen,Yan Zhang,Kaichao Feng,Yang Liu,Su-Xia Li,Qingming Yang,Weidong Han +15 more
TL;DR: CART-30 cell therapy was safe, feasible, and efficient in relapsed or refractory lymphoma and guarantees a large-scale patient recruitment.
Journal ArticleDOI
Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.
Hanren Dai,Wenying Zhang,Xiaolei Li,Qingwang Han,Yelei Guo,Yajing Zhang,Yao Wang,Chunmeng Wang,Fengxia Shi,Yan Zhang,Meixia Chen,Kaichao Feng,Quan-shun Wang,Hong-Li Zhu,Xiaobing Fu,Su-Xia Li,Weidong Han +16 more
TL;DR: It is shown for the first time that donor-derived anti-CD19 CART cells can cause GVHD and regression of extramedullary B-ALL and donor- derived T cells genetically modified to express a CAR targeting the B-cell antigen CD19 harboring 4-1BB and the CD3ζ moiety.
Journal ArticleDOI
Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report.
Wenying Zhang,Yao Wang,Yelei Guo,Hanren Dai,Qingming Yang,Yajing Zhang,Yan Zhang,Meixia Chen,Chunmeng Wang,Kaichao Feng,Su-Xia Li,Yang Liu,Fengxia Shi,Can Luo,Weidong Han +14 more
TL;DR: A phase IIa trial to further assess the safety and efficacy of administering autologous anti-CD20 CART (CART-20) cells to patients with refractory or relapsed CD20+ B-cell lymphoma, and suggests large-scale patient recruitment in a future study.
Journal ArticleDOI
Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer.
Meixia Chen,Jing Nie,Yang Liu,Xiang Li,Yan Zhang,Malcolm V. Brock,Kaichao Feng,Zhiqiang Wu,Xiaolei Li,Lu Shi,Su-Xia Li,Mingzhou Guo,Qian Mei,Weidong Han +13 more
TL;DR: The safety and efficacy of decitabine‐primed re‐sensitization to chemoimmunotherapy is attractive and promising and warrant further large‐scale evaluation of drug‐resistant R/R AT cancer patients with advanced stage disease.
Journal ArticleDOI
An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells
Yajing Zhang,Wenying Zhang,Hanren Dai,Yao Wang,Fengxia Shi,Chunmeng Wang,Yelei Guo,Yang Liu,Meixia Chen,Kaichao Feng,Yan Zhang,Chuanjie Liu,Qingming Yang,Su-Xia Li,Weidong Han +14 more
TL;DR: Combined analyses of laboratory biomarkers with their clinical manifestations before and after salvage treatment showed that the persistent immunosurveillance mediated by CAR-T-19 cells would inevitably potentiate the leukemia-killing effectiveness of subsequent chemotherapy in patients who showed relapse after CAR- T-19-induced remission.